Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 08, 2022

SELL
$0.67 - $3.19 $702,869 - $3.35 Million
-1,049,059 Closed
0 $0
Q1 2022

May 16, 2022

BUY
$2.22 - $3.45 $709,871 - $1.1 Million
319,762 Added 43.85%
1,049,059 $3.14 Million
Q4 2021

Mar 03, 2022

BUY
$2.36 - $3.57 $1.72 Million - $2.6 Million
729,297 New
729,297 $1.93 Million
Q3 2020

Nov 16, 2020

SELL
$1.78 - $4.13 $51,620 - $119,770
-29,000 Closed
0 $0
Q2 2020

Aug 14, 2020

BUY
$1.41 - $2.05 $40,890 - $59,449
29,000 New
29,000 $53,000
Q1 2019

May 15, 2019

SELL
$2.0 - $2.65 $303,846 - $402,595
-151,923 Closed
0 $0
Q3 2018

Nov 14, 2018

BUY
$2.6 - $3.59 $394,999 - $545,403
151,923 New
151,923 $488,000

Others Institutions Holding RIGL

About RIGEL PHARMACEUTICALS INC


  • Ticker RIGL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 172,836,000
  • Market Cap $2.96B
  • Description
  • Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is ...
More about RIGL
Track This Portfolio

Track Walleye Capital LLC Portfolio

Follow Walleye Capital LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Walleye Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Walleye Capital LLC with notifications on news.